Bill > HR5958

This bill, the "Drug-price Transparency for Consumers Act of 2023" or "DTC Act of 2023," aims to amend the Social Security Act to require that direct-to-consumer advertisements for drugs and biologicals (medical products derived from living organisms) include the wholesale acquisition cost (the list price set by the manufacturer) for a 30-day supply or typical course of treatment. The bill provides an exemption for drugs and biologicals with a wholesale acquisition cost of less than $35 for a 30-day supply. The Secretary of Health and Human Services is directed to promulgate regulations to implement this requirement, including visual and audio components, timeframes for updating advertisements, and allowing for a brief statement about potential differences in out-of-pocket costs based on insurance coverage. The bill also authorizes the establishment of a public reporting system to enforce compliance and allows for civil monetary penalties of up to $100,000 for each violation.